Additionally, drug-response analysis from the GDSC database hinted that FAT/FRY subtype ESCC cell lines might be more sensitive to the PIK3Ca inhibitor alpelisib. This evidence concerns the gene PIK3CA and esophageal squamous cell carcinoma.